Supply of betamethasone (as dipropionate) (DIPROSONE) 0.5 mg/g ointment tube by Merck Sharp & Dohme Australia Pty Ltd

Overview

The Therapeutic Goods Act 1989 was enacted to provide a regulatory framework for therapeutic goods, including medicines, medical devices, and blood and blood components, ensuring their quality, safety, and efficacy. The Act aims to protect public health by regulating the manufacture, supply, and advertising of therapeutic goods. One notable aspect of the Act is its provision for the Secretary of the Department of Health and Ageing to grant consent for the supply of goods that do not conform to certain legislative requirements, as long as specified conditions are met. This approach allows for flexibility in the regulation of therapeutic goods while maintaining the overarching goal of protecting public health. The 2013 notice under sections 14 and 14A of the Act, for instance, allowed for the supply of a specific batch of betamethasone ointment despite its non-compliance with labelling requirements, subject to conditions designed to mitigate any potential risks. This demonstrates the Act’s balance between regulatory oversight and pragmatic decision-making to facilitate the availability of necessary therapeutic goods.

Scope and Application

The Therapeutic Goods Act 1989 provides the legislative framework for the regulation of therapeutic goods in Australia. Under sections 14 and 14A, the Act allows for the delegate of the Secretary of the Department of Health and Ageing to give consent for the supply of certain therapeutic goods that do not fully comply with the Therapeutic Goods Order. This legislative provision applies to specific entities and products, such as Merck Sharp & Dohme Australia Pty Ltd and their product betamethasone (as dipropionate) (DIPROSONE) 0.5 mg/g ointment tube [Aust R 144098], which in this case, had labelling that included the details of a previous sponsor instead of the current supplier. The consent provided by the Secretary's delegate is geographically limited to Australia, reflecting the national reach of the Act. The Act's application is further nuanced through its subordinate instruments, which can extend or restrict the scope of its provisions, ensuring that therapeutic goods supplied within Australia meet the required standards of safety, quality, and efficacy.

Key Provisions

The Therapeutic Goods Act 1989, under sections 14 and 14A, allows for the supply of therapeutic goods that do not strictly conform to the requirements of the Therapeutic Goods Orders, subject to certain conditions. In this instance, the delegate of the Secretary of the Department of Health and Ageing has consented to the supply of betamethasone (as dipropionate) (DIPROSONE) 0.5 mg/g ointment tube [Aust R 144098] by Merck Sharp & Dohme Australia Pty Ltd (the Company) (sections 14 and 14A). This consent applies specifically to certain batches of the product (section 15(1)) and is subject to conditions outlined in the notice. The obligations imposed on the parties by this consent include adherence to the specific conditions set forth in the notice. For example, the consent applies only to the specified batches of the product (section 2), and the labels used must be the current ones, which include the details of the previous sponsor (section 3). Additionally, the Company must ensure that any complaints or queries regarding these products are handled promptly (section 4). Failure to comply with the conditions set by the delegate of the Secretary could result in various consequences. Under the Act, breaches of the conditions could lead to civil or criminal penalties. Specifically, the Act provides for penalties including fines and imprisonment for serious or repeated breaches. However, the exact penalties are not specified in the notice and would depend on the nature and severity of the breach, as well as the specific provisions of the Act that are contravened. The Act also provides mechanisms for enforcement and compliance, ensuring that therapeutic goods supplied in Australia meet the necessary standards of safety and efficacy.